PROSTAT KANSERLİ HASTALARDA EVRELEME VETEDAVİ PLANINDA LUMBOPELVİK SPECT/BT’NİN TÜMVÜCUT KEMİK SİNTİGRAFİSİNE KATKISI

Amaç: Prostat kanserli hastalarda kemik metastaz taramasında lumbopelvik SPECT/BT görüntülemenin TVKS’ye katkısını belirlemek ve tedavi yöntemine etkisini araştırmaktı.Materyal ve Metot: 184 hastanın verileri geriye dönük olarak incelendi. TVKS, lumbopelvik SPECT/BT ve her ikisinin birlikte değerlendirilmesiyle tüm hastalar normal, benign, şüpheli ve metastatik olarak yorumlandı. Her metodun kemik metastazını belirlemedeki tanısal parametreleri hesaplandı. Ayrıca lumbopelvik SPECT/BT’nin hasta bazında tanıya katkısı ve tedavi yönetimine etkisi belirlendi.Bulgular: TVKS ile hastaların %22,82’si metastaz açısından şüpheli olarak değerlendirilmiş olup bu oran lumbopelvik SPECT/BT’nin eklenmesiyle belirgin olarak düşmüştür (%22,82 ve %7,61; p

THE CONTRIBUTION OF LUMBOPELVIC SPECT/CT TO WHOLE BODY SCANNING IN STAGING AND THERAPY MANAGEMENT IN PROSTATE CANCER PATIENTS

Objectives: The study aimed to determine the contribution of lumbopelvic SPECT/CT and investigate its effecton management of therapy. Materials and Methods: The data of 184 patients were analyzed retrospectively. All patients were interpretedas normal, benign, suspicious, and metastatic by evaluating WBS, lumbopelvic SPECT/CT, and both. Eachmethod's diagnostic parameters and the contribution of lumbopelvic SPECT/CT to diagnosis and therapymanagement were determined on a patient basis. Results: With WBS, %22.82 of the patients were evaluated as suspicious for metastasis, and this rate decreasedsignificantly with the addition of lumbopelvic SPECT/CT (%22.82 and %7.61; p

PDF

___

1. Amin MB, Greene FL, Edge SB, ve ark. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.
2. Attard G, Parker C, Eeles RA, ve ark. Prostate cancer. The Lancet. 2016;387:70-82.
3. Mottet N, Bellmunt J, Bolla M, ve ark. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618–29.
4. Heidenreich A, Bastian PJ, Bellmunt J, ve ark. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.
5. Pesapane F, Czarniecki M, Suter MB, Turkbey B, Villeirs G. Imaging of distant metastases of prostate cancer. Med Oncol. 2018;35(11):0. (İnternet) http://dx.doi.org/10.1007/s12032-018-1208-2 (Erişim Tarihi: 01.10.2020).
6. Van Den Wyngaert T, Strobel K, Kampen WU, ve ark. The EANM practice guidelines for bone scintigraphy On behalf of the EANM Bone & Joint Committee and the Oncology Committee. Eur J Nucl Med Mol Imaging. 2016;43:1723–38.
7. Horwich A, Hugosson J, de reijke T, ve ark. Prostate cancer: ESMO consensus conference guidelines 2012. Ann Oncol. 2013; 24(5):1141-62.
8. Jambor I, Kuisma A, Ramadan S, ve ark. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2016;55(1):59–67.
9. Iqbal B, Currie GM, Wheat JM, Raza H, Kiat H. The incremental value of SPECT/CT in characterizing solitary spine lesions. J Nucl Med Technol. 2011;39(3):201–7.
10. Zhang Y, Shi H, Li B, Cai L, Gu Y, Xiu Y. The added value of SPECT/spiral CT in patients with equivocal bony metastasis from hepatocellular carcinoma. Nuklearmedizin. 2015;54(06):255–61.
11. Maurer AH. 2013 SNMMI Highlights Lecture: General clinical nuclear medicine: clinical SPECT/CT--time for a new standard of care. J Nucl Med. 2013;54(10):19–28.
12. Bozkurt MF, Demir H, Şanlı Y, ve ark. TSNM, SPECT-CT Hybrid Imaging Procedure Guideline for Tumour Imaging. Nucl Med Semin. 2015;1(1):57–61.
13. Ceylan Y, Özcan Z. Prostat Kanseri Kemik Metastazlarının Saptanmasında Konvansiyonel Tc-99m MDP Kemik Sintigrafisinden SPECT/BT’ye Geçiş ve Kazanımları. Türkiye Klin Nükleer Tıp - Özel Konular. 2019;5(1):1–6.
14. Israel O, Pellet O, Biassoni L, ve ark. Two decades of SPECT/CT – the coming of age of a technology: An updated review of literature evidence. Eur J Nucl Med Mol Imaging. 2019;46(10):1990–2012.
15. Mahaletchumy T, AbAziz A. Incremental value of single-photon emission computed tomography-computed tomography for characterization of skeletal lesions in breast cancer patients. World J Nucl Med. 2017;16(4):303.
16. Teyateeti A, Tocharoenchai C, Muangsomboon K, Komoltri C, Pusuwan P. A comparison of accuracy of planar and evolution SPECT/CT bone imaging in differentiating benign from metastatic bone lesions. J Med Assoc Thail. 2017;100(1):100–10.
17. Palmedo H, Marx C, Ebert A, ve ark. Whole-body SPECT/CT for bone scintigraphy: Diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41(1):59–67.
18. Fleury V, Ferrer L, Colombié M, ve ark. Advantages of systematic trunk SPECT/CT to planar bone scan (PBS) in more than 300 patients with breast or prostate cancer. Oncotarget. 2018;9(60):31744–52.
19. Rager O, Nkoulou R, Exquis N, ve ark. Whole-Body SPECT/CT versus planar bone scan with targeted SPECT/CT for metastatic workup. Biomed Res Int. 2017. 7039406. (İnternet) https://doi.org/10.1155/2017/7039406 (Erişim tarihi 01.10.2020).
20. Guezennec C, Keromnes N, Robin P, ve ark. Incremental diagnostic utility of systematic double-bed SPECT/CT for bone scintigraphy in initial staging of cancer patients. Cancer Imaging. 2017;17(1):1–8.
21. World Medical Association (2013). World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–94.
22. Helyar V, Mohan HK, Barwick T, ve ark. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37(4):706–13